Aim: The purpose of this study was to isolate and characterize the Mannheimia haemolytica and Pasteurella multocida from blood, nasal discharge, and lung tissue of pneumonic goats.
Materials and Methods: A total of 14 goats were investigated for pneumonic pasteurellosis. Of 14 goats, nasal swabs and blood samples were collected from 10 clinically diseased animals. Moreover, lung tissue and heart blood samples were collected during necropsy of four goats died with pneumonia. All the samples were processed for the isolation of M. haemolytica and P. multocida in the laboratory. Bacterial isolates were identified by cultural and biochemical characters and 16S rRNA sequence analysis. All the isolates were subjected to susceptibility testing using commonly used antimicrobials. M. haemolytica isolates were characterized by PHSSA gene detection. P. multocida isolates were characterized by KMT1 gene detection and capsule typing.
Results: On necropsy of dead goats, the pneumonia was characterized as acute fibrinous bronchopneumonia. Bacterial culture revealed the isolation of M. haemolytica (7) and P. multocida (5) of 10 clinical cases. Moreover, M. haemolytica and P. multocida were coisolated from two of the lung tissues. Furthermore, one of the other two lung tissues showed the isolation of M. haemolytica while the other showed recovery of P. multocida. Bacterial isolates were specifically identified by the 16S rRNA sequence analysis. The isolates showed reduced susceptibility to β-lactams, aminoglycosides, and fluoroquinolones . Moreover, the PHSSA and KMT1 genes were specifically detected among M. haemolytica, and P. multocida isolates, respectively. All P. multocida isolates belonged to serogroup A.
Conclusion: The present study reported an occurrence of pneumonic pasteurellosis caused by M. haemolytica and P. multocida in a goat flock.
Objective: The objective of present work was to utilize the potential of nanostructured lipid carriers (NLCs) form improvement in bioavailability of Sertraline as antidepressant drug formulated by emulsification- solvent evaporation technique with some modification. NLC is the blend of solid lipid, liquid lipid and surfactant for encapsulation of poor water soluble actives. Design: A full 32 factorial design was utilized to study the effect of two independent parameters namely solid lipid to liquid lipid concentration and stabilizer concentration on the entrapment efficiency of the prepared NLCs. The sertraline NLC formulation was characterized with respect to particle size, polydispersity index (PDI), zeta-potential, encapsulation efficiency and physical morphology. Result: The NLC formulation had an average diameter of 96.59 nm, PDI of 0.192, zeta-potential of -39.88 mV, and encapsulation efficiency of 97%, respectively. Conclusion: The NLC formulation for sertraline encapsulation has been successfully developed and is suitable for nose to brain delivery system due to their nano-size and sta
This review focuses on the design, synthesis and pharmacological effects of non-steroidal anti-inflammatory (NSAIDs) mefenamic acid which is an anthranilic acid derivative. Mefenamic acid is a non-steroidal anti-inflammatory drug used to treat pain, including menstrual pain. Exploitation of the prodrug approach has the potential to achieve a reduction of mefenamic acid GI (gastrointestinal) intolerance, enhance its bioavailability, mask its unpleasant sensation and prolong its duration of action. Mefenamic acid, an effective NSAID has always been used as an anti-inflammatory and analgesic agent. A brief note on various marketed formulations of mefenamic acid provides an insight of the potential capability of this drug and its future scope.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.